DNLI
Price
$14.69
Change
-$0.21 (-1.41%)
Updated
Jul 3 closing price
Capitalization
2.13B
26 days until earnings call
RGNX
Price
$8.74
Change
+$0.12 (+1.39%)
Updated
Jul 3 closing price
Capitalization
440.4M
25 days until earnings call
Interact to see
Advertisement

DNLI vs RGNX

Header iconDNLI vs RGNX Comparison
Open Charts DNLI vs RGNXBanner chart's image
Denali Therapeutics
Price$14.69
Change-$0.21 (-1.41%)
Volume$613.31K
Capitalization2.13B
REGENXBIO
Price$8.74
Change+$0.12 (+1.39%)
Volume$423.94K
Capitalization440.4M
DNLI vs RGNX Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. RGNX commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (DNLI: $14.69 vs. RGNX: $8.74)
Brand notoriety: DNLI and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 42% vs. RGNX: 38%
Market capitalization -- DNLI: $2.13B vs. RGNX: $440.4M
DNLI [@Biotechnology] is valued at $2.13B. RGNX’s [@Biotechnology] market capitalization is $440.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • RGNX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than RGNX.

Price Growth

DNLI (@Biotechnology) experienced а +1.38% price change this week, while RGNX (@Biotechnology) price change was -0.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.13B) has a higher market cap than RGNX($440M). RGNX YTD gains are higher at: 13.066 vs. DNLI (-27.920). RGNX has higher annual earnings (EBITDA): -122.44M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. RGNX (268M). DNLI has less debt than RGNX: DNLI (48.6M) vs RGNX (79.8M). RGNX has higher revenues than DNLI: RGNX (157M) vs DNLI (0).
DNLIRGNXDNLI / RGNX
Capitalization2.13B440M485%
EBITDA-505.16M-122.44M413%
Gain YTD-27.92013.066-214%
P/E RatioN/AN/A-
Revenue0157M-
Total Cash818M268M305%
Total Debt48.6M79.8M61%
FUNDAMENTALS RATINGS
DNLI vs RGNX: Fundamental Ratings
DNLI
RGNX
OUTLOOK RATING
1..100
5655
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
6055
P/E GROWTH RATING
1..100
9923
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (73) in the Biotechnology industry is in the same range as DNLI (93). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as RGNX (96). This means that DNLI’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (55) in the Biotechnology industry is in the same range as DNLI (60). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's P/E Growth Rating (23) in the Biotechnology industry is significantly better than the same rating for DNLI (99). This means that RGNX’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRGNX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSEGX59.160.79
+1.35%
Morgan Stanley Inst Growth A
ASMNX20.310.27
+1.35%
AQR Small Cap Momentum Style N
SSMHX331.443.12
+0.95%
State Street Small/Mid Cap Equity Index
GSRIX12.800.06
+0.47%
Goldman Sachs Rising Dividend Gr Inv
STREX22.310.10
+0.45%
Sterling Capital Equity Income R6

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.41%
BEAM - DNLI
58%
Loosely correlated
+0.65%
NRIX - DNLI
57%
Loosely correlated
+2.33%
OCUL - DNLI
55%
Loosely correlated
+1.69%
RGNX - DNLI
55%
Loosely correlated
+1.39%
ARWR - DNLI
55%
Loosely correlated
-0.65%
More